^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

durcabtagene autoleucel (PHE885)

i
Other names: PHE885, PHE-885, PHE 885
Associations
Trials
Company:
Novartis
Drug class:
BCMA-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials